Anti-Siglec-15 antibody
US8575316B2 · kind B2 · utility
15Cited by
7References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 7, 2010 |
| Grant date | Nov 5, 2013 |
| Priority date | — |
| Expiry date | Jun 28, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.